ImmuCell Corporation (ICCC)
NASDAQ: ICCCHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ICCC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $99.28M
- P/E (TTM)
- 57.47
- EPS (TTM)
- $0.19
- Dividend yield
- None
- 52-week range
- 4.67 – 12.10
- Day range
- 10.31 – 11.25
- Volume / Avg
- 18.75K / 13.44K
- Beta
- —
- Shares outstanding
- 9.09M
52-week range
ICCC stock today
ImmuCell (ICCC) closed at $10.92 on Nov 20, down 2.41% (-$0.27), versus the S&P 500's 3.70% decline. At this level, ICCC sits near the top of its 52-week range of $4.67 to $12.10: 9.8% below the high, set on Jul 14, 2026 and 133.8% above the low. ICCC is up 77.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 133.3%.
ImmuCell trades at 57.5x its trailing twelve-month earnings per share of $0.19.
Summary generated from market data by MetaCap's automated system. Methodology
About ImmuCell
Company profileImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Paul F. Olivier Te Boekhorst
- Headquarters
- Portland, ME
- Employees
- 73
- IPO year
- 1987
- Website
- immucell.com
Financial highlights
Full financialsIn fiscal 2025, ImmuCell generated $27.6 million in revenue, up 4.3% from fiscal 2024, its 2nd consecutive year of revenue growth. ImmuCell reported a net loss of $1.0 million, compared with a loss of $2.2 million a year earlier. Gross margin was 41.4% (up from 30.0%) and operating margin 6.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $27.64M | $26.49M | $17.47M | $18.57M | $19.24M |
| Growth | +4.34% | +51.64% | -5.90% | -3.51% | +25.43% |
| Net income | $-1.04M | $-2.16M | $-5.77M | $-2.49M | $-78.29K |
| EPS (diluted) | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.10 vs —
ICCC news
All ICCC news- ImmuCell Corporation Reports Third Quarter 2026 Net Income of $953,000Nasdaq
- ImmuCell (ICCC) Q3 2026 Earnings Call TranscriptNasdaq
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026GlobeNewswire
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026GlobeNewswire
- ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?NasdaqZTS, ICCC
- ImmuCell Reports Preliminary Q3 2026 Sales Growth Of 46%;Stock UpNasdaqICCC, ET
- ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales ResultsGlobeNewswire
- Top Research Reports for Alphabet, Mastercard & AbbVieNasdaqMA, ABBV, GOOGL, PPIH
ImmuCell peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs ICCC |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs ICCC |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs ICCC |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs ICCC |
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs ICCC |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs ICCC |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs ICCC |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs ICCC |
Indexes, lists and sector
ImmuCell stock FAQ
What is ImmuCell's stock price today?
ICCC last traded at $10.92 as of Nov 20, 4:00 PM EST, down 2.41% on the day. Prices are delayed at least 15 minutes.
Does ImmuCell pay a dividend?
No. ImmuCell does not currently pay a regular cash dividend.
What is ICCC's P/E ratio?
ICCC trades at a trailing P/E ratio of 57.47.
Who is ImmuCell's CEO?
Mr. Paul F. Olivier Te Boekhorst is the chief executive officer of ImmuCell Corporation, which has about 73 employees.
Has ICCC ever split its stock?
Yes. The most recent ICCC stock split was a 1-for-100 split on Jul 25, 1990.
What is the ICCC 52-week high?
The 52-week high for ICCC is $12.10 and the 52-week low is $4.67. The stock is currently 9.8% below its high.